Zoetis Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ZTS research report →
Range $74 – $95
Price Chart
About the company
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses.
- CEO
- Kristin C. Peck
- IPO
- 2013
- Employees
- 14,500
- HQ
- Parsippany, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a corrective regime after a long slide from the 52-week high, but it has stabilized well above the 52-week low. Price remains below the 200-day average, while the 50-day sits under the 200-day, keeping the longer-term trend cautious rather than repaired.
Street sentiment is mixed-to-cautious: consensus sits at Hold, with 13 Buys, 18 Holds, and no Sells. The average target has drifted to $84.75, only modestly above the current quote, and recent actions skew toward downgrades and target cuts rather than fresh upside calls.
The earnings profile is constructive but not flawless. Zoetis has beaten EPS in 7 of the last 8 quarters, including a 15.9% beat most recently, while next-year EPS is still expected to rise to 6.3728 from 5.88 TTM. Shareholders should watch whether revenue stabilizes after a 1.3% YoY decline.
No discretionary insider buying or selling stands out. Recent activity is dominated by award grants, exempt transactions, and vesting-related flows, including large equity awards to executives and directors, which read as routine compensation rather than a directional signal.
Profitability remains strong, with a 71.6% gross margin, 37.91% operating margin, and 26.41% net margin. Growth has softened, with revenue down 1.3% YoY and earnings down 11.8% YoY, but free cash flow of $3.525 billion and a 10.74% FCF yield keep the cash engine solid.
Zoetis still screens as a premium animal-health name, supported by high margins and consistent cash generation. Versus the sector, the valuation is not cheap at 12.28x earnings, but the quality profile remains stronger than most drug manufacturers in specialty and generic pharma.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $32.14B
- P/E
- 13.72
- Fwd P/E
- 12.51
- PEG
- -16.30
- P/S
- 3.45
- P/B
- 10.07
- EV/EBITDA
- 10.62
- Div Yield
- 2.62%
- Gross Margin
- 71.02%
- Op Margin
- 36.26%
- Net Margin
- 26.15%
- ROE
- 76.40%
- ROIC
- 20.92%
Latest fiscal year · YoY change
- Revenue
- $9.47B+2.3%
- Gross Profit
- $6.67B+4.3%
- Op Income
- $3.60B
- Net Income
- $2.67B+7.5%
- EPS
- $6.03+10.2%
- OCF Growth
- -1.7%
- FCF Growth
- -0.7%
- 52W High
- $132.49
- 52W Low
- $68.77
- 50D MA
- $77.06
- 200D MA
- $90.66
- Beta
- 0.68
- RSI (14)
- 46
- Avg Volume
- 4.49M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Zoetis delivered a soft third quarter with revenue down 1%, but management said execution and promotions helped limit share loss and raised full-year EPS guidance while narrowing revenue guidance to the high end of the range.· November 5, 2026
- Q3 revenue was $2.4 billion, down 1% reported and organic operationally; adjusted EPS was $1.75, up 1%.
- U.S. revenue fell 6% while international revenue rose 4%, with livestock and diagnostics offsetting weakness in companion animal.
- Adjusted gross margin was 71%, down 30 basis points reported and 60 basis points operationally, pressured by pricing actions, mix, and inventory-related charges.
- Management narrowed 2026 revenue guidance to $9.22 billion-$9.32 billion and raised adjusted net income guidance to $2.6 billion-$2.64 billion and adjusted diluted EPS to $6.25-$6.35.
- The company said promotional investments slowed dermatology share loss and Simparica Trio held a 22.5% U.S. share, while several launches remain on track for 2026-2027.
Zoetis reported third-quarter 2026 revenue of $2.4 billion, down 1% on both a reported and organic operational basis, driven by a 1% price decline and flat volume. Adjusted EPS was $1.75, up 1%, and adjusted net income was $720 million, down 7% on an organic operational basis. Adjusted gross margin was 71%, down 30 basis points reported and 60 basis points operationally; adjusted operating expenses were $749 million, flat operationally. By segment, U.S. revenue was $1.2 billion, down 6%, and international revenue was $1.1 billion, up 4%. For full-year 2026, management narrowed revenue guidance to $9.22 billion-$9.32 billion, representing an organic operational decline of 2% to 1%; raised adjusted net income guidance to $2.6 billion-$2.64 billion, representing an organic operational decline of 7% to 5%; and raised adjusted diluted EPS guidance to $6.25-$6.35.
Kristin Peck said the quarter reflected a challenging companion animal environment, but she emphasized that Zoetis’ diversified portfolio and targeted execution helped defend leadership positions. She framed the strategy around three priorities: leveraging portfolio breadth, expanding access to established franchises, and advancing innovation. Her tone was cautious but constructive, repeatedly noting that the company is not assuming an improvement in macro conditions or competition, while staying confident in long-term growth drivers such as innovation, diagnostics, and livestock.
Jay Saccaro highlighted the quarter’s core financials and said results were in line with expectations. He cited $2.4 billion in revenue, $1.75 adjusted EPS, 71% adjusted gross margin, $749 million of adjusted operating expenses, and $720 million of adjusted net income, plus the $78 million impairment charge on previously acquired in-process R&D assets. He also noted $2.4 billion distributed to shareholders through the third quarter of 2026 via buybacks and dividends, and said the company remains focused on R&D, disciplined bolt-on M&A, and efficiency to support gross margin and SG&A over time.
Analysts focused on how long the gross-to-net/promotional actions would last, whether dermatology and parasiticide share loss is stabilizing, and what 2027 may look like. Management said the promotions are helping slow derm share loss, with U.S. dermatology share loss improving from 7 points in Q2 to 4 points in Q3, and Simparica Trio holding a 22.5% U.S. share. On 2027, Jay said it is too early for specific guidance and that the company will be conservative, not assuming macro improvement or a change in competitive dynamics. Questions also covered Cytopoint long-acting, Simparica Duo, and channel/distributor strategy; management said Cytopoint long-acting is on track for approval this year and launch in the first half of next year, and Simparica Duo is expected to be an RX product approved this year and launched next year.
The bull case from the call is that Zoetis still has multiple growth levers despite the soft pet-care market: livestock grew 7%, diagnostics grew 13%, and international Simparica Trio and OA pain products are gaining traction. Management also pointed to a strong innovation slate, with several lifecycle and breakthrough launches on track for 2026-2028, and said commercial actions are helping defend share in key franchises.
The bear case is that companion animal remains under pressure from softer clinic visits, affordability issues, and intense competition, especially in dermatology, where global sales fell 16% and U.S. dermatology share loss remains a concern. Management also signaled that 2027 may still face the same macro and competitive headwinds, and that the new product pipeline is expected to contribute only limited revenue next year. Gross margin is also under pressure from pricing and mix, and management indicated these gross-to-net investments may need to continue until share stabilizes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 406.32M
- Float Shares
- 405.46M
of shares held by institutions
1,496 13F filers
Buy/sell ratio 4.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ZTS, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Buy | Oct 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Shelley Moore CapitoSenate · WV | Sell | Oct 21, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Sep 18, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 11, 26 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Sep 25, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jul 17, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jul 7, 26 | Filing → |
| Byron DonaldsHouse · FL19 | Buy | Jun 9, 26 | Filing → |
| Byron DonaldsHouse · FL19 | Buy | Jun 9, 26 | Filing → |
| Chuck FleischmannHouse · TN03 | Buy | Jun 9, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 16, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 1, 26 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 47.78M | ▲ 5.47M |
| Blackrock, Inc. | 39.43M | ▲ 3.85M |
| Vanguard Capital Management LLC | 26.03M | ▼ 44.86K |
| Vanguard Portfolio Management LLC | 23.86M | ▼ 106.95K |
| State Street Corp | 19.71M | ▲ 37.65K |
| State Farm Mutual Automobile Insurance Co | 15.89M | 0 |
| Geode Capital Management, LLC | 13.27M | ▼ 16.99K |
| Fil Ltd | 10.64M | ▲ 5.26M |
| Wellington Management Group Llp | 9.42M | ▼ 726.20K |
| Morgan Stanley | 8.88M | ▼ 5.27M |
| Invesco Ltd. | 7.97M | ▲ 2.44M |
| Nordea Investment Management Ab | 6.31M | ▼ 286.33K |
Held by 2,125 ETFs
Biggest fund positions in ZTS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 26 | Stetter Mark | other | 5.852 |
| Oct 9, 26 | PECK KRISTIN C | other | 720.144 |
| Oct 9, 26 | Esch Kevin | other | 360.073 |
| Oct 9, 26 | Driscoll Rimma | other | 277.772 |
| Oct 9, 26 | FULLER JULIE | other | 367.788 |
| Oct 9, 26 | Sarbaugh Keith | other | 303.49 |
| Oct 9, 26 | Ferran Astorga Jeannette | other | 52.983 |
| Oct 9, 26 | Nayak Abhay U | other | 321.495 |
| Oct 9, 26 | Lagano Roxanne | other | 367.788 |
| Sep 30, 26 | FULLER JULIE | other | 799 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ZTS coverage
Recent articles, reports, and earnings notes.

Zoetis (ZTS): Growth Reset After Companion Animal Slowdown
Zoetis remains a high-quality animal health leader, but slower companion animal demand, heavier discounting, and a reduced 2026 outlook keep the stock in Hold territory. Livestock and diagnostics are offsetting some weakness, yet the earnings reset is still underway.

Zoetis’ selloff is the valuation reset long-term bulls needed
Zoetis’ 5.97% selloff looks like a concentrated U.S. pet-demand reset, not a broken animal-health franchise. At 12.39x trailing earnings and a 37.0% operating margin, ZTS offers long-term bulls a better entry than its old premium valuation did.

Zoetis (ZTS): Premium Animal Health Recovery Play
Zoetis remains a Buy for investors willing to wait for a premium pet-care rebound. Strong margins, cash flow, and a deep pipeline are offset by softer U.S. companion-animal trends and elevated leverage.
Want a deeper read on ZTS?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Zoetis Receives USDA License for Poulvac® Procerta® HVT-ND-ILT Vaccine for Chickens
businesswire.com · Nov 19
Zoetis Inc. (ZTS) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 16
Eurizon Capital SGR S.p.A. Sells 75,462 Shares of Zoetis Inc. $ZTS
defenseworld.net · Nov 16
Zoetis Inc. $ZTS Shares Sold by Commonwealth Equity Services LLC
defenseworld.net · Nov 14
Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief
zacks.com · Nov 12
SCHD-Inspired 4-Factor Dividend Growth Strategy Selections For November 2026
seekingalpha.com · Nov 12
Zoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic Dermatitis
businesswire.com · Nov 11
Zoetis to Participate in the Jefferies Global Healthcare Conference in London
businesswire.com · Nov 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice